KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.

Lorenzo Antonuzzo, Hidenori Takahashi, Joon Oh Park, Aumkhae Sookprasert, Roopinder Gillmore, Sheng-Shun Yang, Juan Cundom, Mila Petrova, Gina Vaccaro, Marielle Holmblad, Magdalena Żotkiewicz, Julie Wang, Nana Rokutanda, Do-Youn Oh

Oncologist 30(7) oyaf148

PMID40622010
PMCIDPMC12230790
DOI10.1093/oncolo/oyaf148
发表日期2025-07-07
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1.:森林图/亚组分析图。
摘要

摘要

INTRODUCTION: We assessed immune-mediated adverse events (imAEs) in the TOPAZ-1 (NCT03875235) study of durvalumab plus gemcitabine and cisplatin (GemCis) in advanced biliary tract cancer (aBTC). METHODS: Participants were randomized 1:1 to durvalumab (1500 mg) or placebo, plus GemCis (gemcitabine [1000 mg/m2] and cisplatin [25 mg/m2]) intravenously, followed by durvalumab (1500 mg) or placebo Q4W. We assessed imAE incidence, time to onset (TTO), and association with overall survival (OS). RESULTS: In durvalumab (n = 338) versus placebo (n = 342), imAEs were reported in 13.9% versus 4.7% of participants, with median TTO of 127.0 versus 86.5 days, respectively. OS HR for durvalumab versus placebo in participants with imAEs was 0.59 (95% CI, 0.30-1.23) and was 0.83 (95% CI, 0.70-1.00) in participants without imAEs. CONCLUSIONS: Durvalumab demonstrated an OS benefit versus placebo in aBTC, irrespective of imAEs, which were mostly low grade and manageable. The results in these subgroups were consistent with the overall primary analysis. TRIAL REGISTRATION: ClinicalTrials.gov NCT03875235.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.imAE frequency and overall survival in TOPAZ-1 participants. Dots represent censored observations. (A) Overall frequency of imAEs over time for participants treated with durvalumab plus GemCis or placebo plus GemCis. The percentage of participants with an event is the number of participants who experienced ≥1 imAE at each time interval divided by the number of participants who experienced ≥1 imAE at any time; includes first imAE only, regardless of grade. (B) OS in participants with an imAE treated with durvalumab plus GemCis or placebo plus GemCis. (C) OS in participants without imAEs treated with durvalumab plus GemCis or placebo plus GemCis. (D) OS in participants treated with durvalumab plus GemCis by imAE status. Panels B-D: Participants not known to have died at the time of analysis are censored at the last recorded date on which the participant was last known to be alive. Abbreviations: CI, confidence interval; GemCis, gemcitabine and cisplatin; HR, hazard ratio; imAE, immune-mediated adverse event; n , number of participants; NC, noncalculable; OS, overall survival. Figure originally presented at the European Society for Medical Oncology Congress 2022 by Lorenzo Antonuzzo et al. Reused with permission.
非 KM Figure